Continued Elevation of Plasma IL-4 and IL-17 Predicts the Progression from VMC to DCM

Table 2

Adjusted relative risks (95% confidence interval) of incident DCM after three months.

Baseline characteristics	Univariate model^‡	Multivariate model^§
Age (yrs)	1.08 (1.06-1.10)^†	1.036 (1.008-1.066),
Male	1.88 (1.24-2.86)^†	NS
LVEF (%)	0.88 (0.86-0.90)^†	0.895 (0.866-0.925), ^†
Ln(IFN-γ)	1.85 (1.14-2.98)	NS
Ln(IL-4)	1.06 (1.05-1.07)^†	1.039 (1.022-1.055), ^†
Ln(IL-17)	3.65 (2.56-5.20)^†	5.241 (2.806-9.789), ^†
Ln(NT-pro-BNP)	1.236 (1.102-1.386)^†	NS
Coxsackievirus B5-IgM (+)	4.19 (2.42-7.25)^†	NS
Coxsackievirus B3-IgM (+)	6.75 (3.68-12.37)^†	NS
Cytomegalovirus-IgM (+)	6.23 (3.83-10.13)^†	NS
Enterovirus RNA (+)	5.73 (3.18-10.33)^†	NS
Anti-ANT antibody (+)	7.53 (2.99-18.96)^†	NS
Anti-β1R antibody (+)	4.72 (3.06-7.27)^†	NS
Anti-MHC antibody (+)	2.72 (1.77-4.19)^†	NS
Anti-CaC antibody (+)	3.45 (2.24-5.33)^†	NS

Ln: natural logarithmic transformation. ^‡Model 1: univariate model. ^§Model 2: multivariate model, all variables were entered into the model. ^†. .